Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF18A | Q8NI77 | 14/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30600636 | 1.00 | KIF18A (0.41) | KIF18AKMT2AMEN1GBA1KDM4E | |
| SCHEMBL22148549 | 0.84 | KMT2A (0.53) | KIF18AKMT2AMEN1GBA1KDM4E | |
| SCHEMBL31392245 | 0.79 | KDM4E (0.36) | KIF18AKMT2AMEN1GBA1KDM4E | |
| SCHEMBL30522475 | 0.79 | KIF18A (0.48) | KIF18AALDH1A1 | |
| SCHEMBL26618020 | 0.77 | HTT (0.45) | KIF18AKMT2AMEN1GBA1KDM4E | |
| SCHEMBL22119420 | 0.77 | NOS3 (0.44) | KIF18AKMT2AMEN1GBA1KDM4E | |
| SCHEMBL30643068 | 0.77 | HTT (0.45) | KIF18AKMT2AMEN1GBA1KDM4E | |
| SCHEMBL31426977 | 0.77 | KIF18A (0.36) | KIF18AKMT2AMEN1GBA1 | |
| SCHEMBL25182383 | 0.76 | KDM4E (0.37) | KMT2AMEN1GBA1KDM4EHPGD | |
| SCHEMBL31426975 | 0.75 | RBP4 (0.56) | KIF18AKDM4EHPGDHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250264-A1 | KIF18A INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-08-07 | — | — | US | disclosed |
| EP-4509505-A1 | KIF18A INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023217232-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| CN-116903605-A | KIF18A inhibitor and application thereof | 武汉人福创新药物研发中心有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023198209-A1 | KIF18A INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2023-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250264-A1 | KIF18A INHIBITOR AND USE THEREOF | KIF18A, KIF18B, KIF15 | KIF18A 1/4885KMT2A 141/4885MEN1 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.